A long conversation with your physician — about what we know, what we don't, and whether this is right for your goals — before anything is administered.
You sit down with your physician for a real conversation — about what you're hoping for, what's known, and what isn't. If a birth-tissue-derived cellular product turns out to be the right fit, the visit itself is a short, directed injection: about 45 to 60 minutes, in-clinic, by your provider.
The products we use — from the New Life Medical Service line (Restor+, Regain, Renyte, Cytosomes) — come from donated human birth tissue, collected at healthy normal births from screened volunteer donors. We want you to know exactly what that means. They are considered investigational and experimental, are not FDA-approved or licensed for this use, and are intended for homologous use only.
You'll receive that disclosure in writing at consent — not buried in a packet, but walked through with you. Expected response, alternatives, why your provider thinks this is (or isn't) the right tool for your goals: all on the table, before anything begins.
Product line · Restor+ · Regain · Renyte · Cytosomes
Who it helps.
This is an emerging field. We approach it conservatively — and we'd rather you leave understanding the evidence than leave with a product you didn't need.
Is there something beyond skincare and injectables? This is one of the tools being explored for tissue repair and skin quality — and we'll tell you where it might fit.
What it can do, what it can't, what's marketing — straight from a physician, not a sales pitch. If it's not right for you, we'll tell you that too.
The science is still being written. You'll know what's evidence, what's promising, and what's unproven — before you decide anything.
Cell therapy doesn't start with a syringe — it starts with a long conversation. Here is the path a thoughtful first cycle follows.
History, imaging if relevant, goal-setting, written consent. We discuss what current evidence supports — and what it doesn't — for your specific indication.
A directed in-clinic injection of about 45 to 60 minutes, performed by your physician. You leave with a written plan for what to expect over the next 4 to 8 weeks.
Structured follow-up: what changed, what didn't, whether a second session is indicated. For some patients, one is enough; for others, a second visit consolidates the response.
If response is durable, follow-up is conversational — once or twice a year, integrated with the rest of your longevity work, not a recurring sales cycle.
Stem-cell protocols invite hard questions — and they should. Here are the ones we hear most, answered the way your physician would answer them in the room.
No — and we say so out loud. The birth-tissue-derived products we use are considered investigational and experimental, are not FDA-approved or licensed for this use, and are intended for homologous use only. You'll receive that disclosure in writing at consent, walked through with you — not buried in a packet.
From donated human birth tissue — collected at healthy normal births from screened volunteer donors, through the New Life Medical Service product line. No embryonic or fetal material is involved. Donor screening and processing happen upstream of us; we'll share the documentation if you want to read it.
That depends entirely on the indication, your physiology, and what's realistic — which is exactly what the consultation is for. We'd rather you leave understanding the evidence than leave with a product you didn't need. If a different tool fits your goal better, we'll tell you.
Maybe. The honest answer is that candidacy is decided in conversation with your physician — after we understand your goal, your medical history, what you've tried, and what the current evidence supports. For some patients, the right answer is not yet, or not this.
Different tools from overlapping families. Exosomes are cell-signaling vesicles; Ariessence PDGF+ is a recombinant alternative with no donor-derived material. Stem-cell products are one option among several — and for many patients, one of the others is the better fit. Your provider will help you choose.
A short, directed injection — about 45 to 60 minutes, in-clinic, by your provider. The long part happens beforehand: the consultation, the written consent, the conversation about expected response and alternatives. Nothing is administered until you've had that.
Stem-cell protocols are physician-directed and individualized. We will discuss candidacy, alternatives, and investigational status in detail before any product is administered.
Plus: how we’d use a summer with the schedule on your side. One page, refreshed each month.
Read this month →